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Key points 
 
Question: Is weight-for-length (WFL) or body mass index (BMI) in children below 2 years a 
better predictor of future health outcomes? 
 
Findings: In this prospective study based in two birth cohorts, being ever overweight (vs. 
never overweight) during 6‒24 months provided adjusted estimates for early adolescent 
cardio-metabolic outcomes (fat-mass index, insulin resistance, metabolic risk score) that did 
not differ greatly across WFL and BMI cut-points. 
 
Meaning: Choice of WFL vs. BMI to define overweight in the first 2 years of life does not 
greatly affect the associations with cardio-metabolic outcomes at early adolescence. 
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Abstract 
 
Importance: The American Academy of Pediatrics currently recommends weight-for-length 
(WFL) for assessment of weight status in children <2 years, but body mass index (BMI) for 
children above 2 years. Yet the clinical implications of using WFL vs BMI in children <2 
years as a predictor of future health outcomes remains understudied. 
Objective: To compare associations of overweight based on WFL vs BMI in children <2 
years with cardio-metabolic outcomes in early adolescence. 
Design: Prospective study of two birth cohorts in United States (Project Viva) and Belarus 
(Promotion of Breastfeeding Intervention Trial, PROBIT) 
Main exposure: Overweight by Centers for Disease Control and Prevention (CDC) 
WFL≥95th percentile, World Health Organization (WHO) WFL ≥97.7th percentile or WHO 
BMI ≥97.7th percentile at 6, 12, 18 or 24 months 
Main outcomes and measures: Fat-mass index, insulin resistance, metabolic risk score, 
obesity (primary outcomes); height and body mass index z-scores, sum of skinfolds, waist 
circumference, systolic blood pressure (secondary outcomes) in early adolescence 
Results: Our analysis included 919 (50.1% male, 65.1% white ethnicity) children from 
Project Viva and 12747 (48.7% male, 100% white ethnicity) from PROBIT. During 6‒24 
months, 22.4%, 17.4% and 17.5% of children in Project Viva, and 29.1%, 24.1% and 24.5% 
of children in PROBIT, were overweight at any of the four timepoints using CDC WFL, 
WHO WFL and WHO BMI cut-points, respectively. After adjusting for maternal and child 
characteristics, being ever overweight (vs. never overweight) during 6‒24 months of age was 
associated with higher likelihood of adverse cardio-metabolic risk markers in early 
adolescence, yet associations did not differ greatly across WFL and BMI cut-points in either 
cohort [e.g. for fat-mass index (in kg/m2) Project Viva ‒ CDC WFL: β 0.9 (95% CI 0.5,1.4); 
WHO WFL: 1.1 (0.6,1.6); WHO BMI: 1.4 (0.9,1.9); PROBIT ‒ CDC WFL: 0.5 (0.4,0.6); 
WHO WFL: 0.6 (0.5,0.7); WHO BMI: 0.6 (0.5,0.6)]. Neither growth metric in infancy was 
superior over the others, based on F-statistics. Findings were similar for insulin resistance, 
metabolic risk score, obesity and secondary outcomes. 
Conclusions: Choice of WFL vs. BMI to define overweight in the first 2 years of life does 
not greatly affect the associations with cardio-metabolic outcomes in early adolescence. 
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Introduction 
 Physical growth of children is a well-recognized indicator of subsequent health and 
wellness.1,2 The American Academy of Pediatrics and Centers for Disease Control and 
Prevention (CDC) currently recommend using weight-for-length (WFL) for assessment of 
overweight in children below 2 years of age;3 it is also a predominant standard used 
internationally.4 WFL percentile curves do not, however, reflect the age-dependent variation 
of weight or length with age. The World Health Organization (WHO) has provided body 
mass index (BMI)-for-age curves for children 0‒5 years, which overcomes this limitation.5  
As both CDC6 and WHO5 charts are available, clinicians and researchers now have a 
choice of growth charts and anthropometric measures to use. It is therefore important to 
understand how they compare in predicting later clinical outcomes, as clinicians might prefer 
to use the metric that more strongly predicts later health. Yet few studies have compared 
these anthropometric measures in terms of their associations with direct measures of 
adiposity and cardio-metabolic risk later in life. Rifas-Shiman et al. previously showed that 
WFL and BMI cut-points for overweight in the first 2 years of life provided similar estimates 
of obesity risk at 5 years.7 Roy et al. observed that high BMI at ages 2‒6 months was more 
strongly associated with obesity at 2 years than high WFL.8 To our knowledge, no studies 
have compared being overweight by WFL or BMI percentiles in the first 2 years of life with 
respect to later adiposity or other cardio-metabolic risk markers other than BMI, such as 
insulin resistance or metabolic risk score. 
 To address these gaps, we used data from two longitudinal cohorts [Project Viva9 and 
the Promotion of Breastfeeding Intervention Trial (PROBIT)10] to compare associations 
between being overweight by CDC WFL, WHO WFL or WHO BMI cut-points in the first 2 
years of life and cardio-metabolic outcomes in early adolescence. Analyzing data in two 
different populations with different confounding structures enables us to assess the robustness 
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of the observed associations. We hypothesized that being overweight in the first 2 years by 
any of the three cut-points would provide similar estimates of association. 
Methods 
Study populations 
i. Project Viva: Project Viva is an ongoing prospective cohort study of pre- and perinatal 
influences on maternal, fetal and child health, as detailed elsewhere.9 Mothers provided 
written informed consent at enrollment and follow-up visits, and children provided verbal 
assent at the early adolescent visit. The Institutional Review Board of Harvard Pilgrim 
Health Care approved the project in line with ethical standards established by the 
Declaration of Helsinki.  
During research examinations in infancy (median 6.3 months; range 4.9–10.6 
months), trained research assistants measured weight and length using standardized 
protocols.11,12 We also obtained additional data on weight and length from medical 
records, where pediatric clinics recorded these measures at each well-child visit during 
infancy and early childhood (<2 years). As described previously,13 clinicians used the 
paper and pencil technique for measuring recumbent length for infants 0-2 years at 
pediatric clinics. We applied a correction algorithm to account for the systematic 
overestimation of lengths resulting from this technique.13 Of 2128 live singleton births, 
we included 919 (43.2%) children who had a measure of weight and length at 6, 12, 18 or 
24 months (within ±2 months at each timepoint) and at least one outcome measure at the 
early adolescent visit (median 12.9 years) (eFigure 1). 
ii.  PROBIT: PROBIT is a cluster-randomized trial of breastfeeding promotion intervention 
in the Republic of Belarus. The design of PROBIT has been published previously.14 The 
initial PROBIT trial and subsequent follow-ups were approved by the Belarussian 
Ministry of Health and received ethical approval from the McGill University Health 
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Centre Research Ethics Board, the Institutional Review Board at Harvard Pilgrim Health 
Care, and the Avon Longitudinal Study of Parents and Children (ALSPAC) Law and 
Ethics Committee. A parent or legal guardian provided written informed consent in 
Russian at enrollment and at the follow-up visits, and all children provided written assent 
at the 11.5-year visit. 
Polyclinic pediatricians measured infant weight and length (with a length board) at 
follow-up visits at 1, 2, 3, 6, 9 and 12 months; home visits were made when polyclinic 
visits were missed.14 We also obtained additional data from polyclinic charts, where the 
study pediatricians recorded length/height and weight data at each well-child visit 
between 12 months and 6.5 years 10 We had no information on the method of length 
measurement in the data extracted from the charts, but we have no reason to think that the 
pediatricians changed their method of length measurement until upright height 
measurement replaced supine length. Of 17,046 healthy, singleton, term live births, we 
studied 12,747 (74.8%) children who had a measure of weight and length at 6, 12, 18 or 
24 months (within ±2 months at each timepoint) and at least one outcome measure at the 
early adolescent visit (median 11.5 years) (eFigure 1). 
Exposure: Infant and child overweight status 
In both cohorts, we used length and weight measurements at 6, 12, 18, and 24 months 
(within ±2 months at each time point) to derive sex-specific CDC WFL, WHO WFL, and 
age- and sex-specific WHO BMI percentiles. The main exposures were being overweight at 
any of the four time points (“ever overweight”) between 6 and 24 months using each of three 
cut-points: CDC WFL ≥95th percentile, WHO WFL or BMI ≥97.7th percentile. In secondary 
analyses, we examined overweight status at each individual time point between 6 and 24 
months. We also categorized children according to number of time points overweight 
between 6 and 24 months (range 0–4) for each of the three cut-points. As few children were 
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overweight at all four time points, we combined those children with those who were 
overweight at any three time points. 
Outcomes: Early adolescent body composition and cardio-metabolic risk markers 
At 12.9 years (range 11.9–16.6 years) in Project Viva, and 11.5 years (10.2–14.5 
years) in PROBIT, we obtained the following measures of body composition and cardio-
metabolic risk markers:  
i. Body composition: As detailed previously, trained research assistants (in Project 
Viva15,16) and pediatricians (in PROBIT10,17,18) measured child’s weight, standing height, 
waist circumference (WC), subscapular (SS) and triceps (TR) skinfolds, and foot-to-foot 
bio-impedance fat mass. In both cohorts, we calculated BMI, derived age- and sex-
specific height and BMI z-scores using CDC reference data,6 and defined obesity as BMI 
≥95th percentile (vs BMI < 95th percentile) in accordance with current guidelines of the 
American Academy of Pediatrics.19 We calculated the sum of the SS and TR skinfolds 
and fat mass index (FMI=fat mass/height2). 
ii. Cardio-metabolic risk markers: Trained research assistants (in Project Viva) and 
pediatricians (in PROBIT) measured the child’s systolic blood pressure (SBP) using 
calibrated automated oscillometric monitors, as detailed previously.12,20 We calculated 
age-, sex- and height-specific SBP z-scores according to the 2017 American Academy of 
Pediatrics BP reference for adolescents.21 In both cohorts, we collected blood specimens 
after a minimum 8-hour fast22,23 and measured glucose and insulin as detailed 
previously,18,20,24 calculated insulin resistance using the homeostasis model assessment 
(HOMA-IR) and transformed the HOMA-IR values using natural logarithms to normalize 
the distribution. Furthermore, we measured high-density lipoprotein cholesterol (HDL-C) 
and triglycerides in Project Viva, and apolipoprotein A1 (Apo A1) in PROBIT, according 
to standard protocols.20,24 We calculated cohort-specific metabolic risk z-scores using the 
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following variables: in Project Viva,24 the average of within-cohort age- and sex-specific 
WC, SBP, triglycerides (log transformed), HDL cholesterol (inverted), and HOMA-IR 
(log transformed); in PROBIT,25 the average of age- and sex-specific WC, SBP, Apo A1, 
fasting insulin and glucose. This cluster of factors comprising the metabolic risk score 
were first formalized by the World Health Organization26 and the National Cholesterol 
Education Program Adult Treatment Panel III.27 Previous studies by Morrison et al.28,29 
demonstrated that children with high metabolic risk score have an increased risk of 
developing type 2 diabetes, cardiovascular disease and metabolic syndrome adulthood, 
suggesting its importance in children. In PROBIT, cardio-metabolic risk markers were 
measured using frozen dried bloodspots. Neither triglycerides nor HDL-cholesterol could 
be validly measured from those samples, and Apo-A1 was therefore used as a surrogate 
for dyslipidemia as previously defined by Bachorik et al.30 
Statistical analysis 
 We assessed for agreement between overweight by CDC WFL, WHO WFL and 
WHO BMI cut-points using kappa statistics. We used multivariable linear (for continuous 
outcomes) and logistic regression (for obesity) to examine associations between being ever 
overweight (vs. never overweight) in the first 2 years and cardio-metabolic outcomes in early 
adolescence, adjusting for the following covariates in each cohort: Project Viva ‒ maternal 
age (<20, 20-34 or ≥35 years), marital status (married/co-habitating or not married), 
educational attainment (non-university vs university educated), pre-pregnancy BMI, total 
gestational weight gain, smoking history (never, smoked prior to pregnancy or smoked during 
pregnancy), glucose tolerance status (normoglycemia, isolated hyperglycemia, impaired 
glucose tolerance or GDM), gestational hypertensive disorders (normal blood pressure, 
gestational hypertension, chronic hypertension and pre-eclampsia), gestational age at delivery 
and child race/ethnicity (white, black, Hispanic, Asian or others), sex (male or female), birth-
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weight-for-gestational-age z-scores, breastfeeding status at 6 months (formula only, weaned, 
mixed feeding or breastmilk only) and age at outcome measurement; PROBIT ‒ maternal age 
(<20, 20-34 or ≥35 years), maternal BMI at 6.5 years (as a proxy for BMI before pregnancy), 
educational attainment (did not complete or completed university), marital status 
(registered/unregistered marriage or unmarried), smoking during pregnancy (yes or no), and 
child gestational age at delivery, sex (male or female), birth-weight-for-gestational-age z-
scores and age at outcome measurement. 
 We also assessed associations of overweight at each “time point” (6, 12, 18, and 24 
months), or the number of time points with overweight, with adiposity and cardio-metabolic 
risk in early adolescence in both cohorts. For all analyses of PROBIT data, we accounted for 
clustered measurements within hospitals/polyclinics by including a random effect term for 
hospital/polyclinic but did not adjust for intervention vs. control arms, as earlier analyses 
showed no differences in early adolescent cardio-metabolic outcomes between these two 
study arms.18,20 
To compare CDC WFL, WHO WFL and WHO BMI as predictors of adiposity and 
cardio-metabolic outcomes, we used the overall F-statistic from linear models predicting each 
of these outcomes31 which reflect the predictive values of the models. At each timepoint 
within each cohort, the models for CDC WFL, WHO WFL and WHO BMI contain the same 
number of covariates. Hence, models with larger F-statistics are more strongly predictive of 
outcomes than models containing a different growth metric. We have also set a value of 5% 
greater difference between largest and second-largest F-statistic values to indicate a 
“meaningful” advantage for the model with the larger value, as described previously by 
Kleinman et al.31 In our study, the use of language around prediction connotes a temporal 
relationship, that the exposure (i.e., overweight by CDC or WHO growth metrics during 6‒24 
months) precedes the subsequent outcome and does not refer to “prediction modeling”. We 
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analysed all data using Stata version 15 (StataCorp, Texas, USA), conducted all statistical 
analyses as 2-sided and defined statistical significance at an α-level of 0.05. 
Results 
 Table 1 describes the characteristics of participating children from both cohorts. Over 
the period spanning 6 to 24 months, 22.4%, 17.4% and 17.5% of children in Project Viva, 
and 29.1%, 24.1% and 24.5% of children in PROBIT were ever overweight using CDC WFL, 
WHO WFL, and WHO BMI cut-points, respectively. In both cohorts, overweight children 
had a higher birthweight-for-gestational age z-score and were more likely to have mothers 
who smoked during pregnancy. In early adolescence, children in Project Viva generally had 
higher adiposity than children in PROBIT (Table 2).  
We observed strong intra-class correlations between CDC and WHO z-scores, and 
agreements between overweight by CDC WFL, WHO WFL and WHO BMI cut-points in 
both cohorts (eTable 1). In Project Viva, we observed no differences in overweight 
prevalence between included and excluded children. Those included in the study however, 
were more likely to have mothers who were older (≥35 years), university-educated and to 
have breastfed at 6 months but less likely to have smoked during pregnancy than those who 
were excluded. In PROBIT, the differences in characteristics and overweight prevalence 
between included and excluded children were small overall (eTable 2). 
 In both cohorts, we found that ever overweight (vs. never overweight) at any of the 
four time points in the first 2 years was associated with higher FMI (Figure 1A), BMI z-
score, sum of SS and TR skinfolds, and WC (eTable 3) in early adolescence. Significant 
associations with higher HOMA-IR and metabolic risk z-score were observed only in 
PROBIT (Figures 1B-C), perhaps because of the relatively small number of Project Viva 
children with fasting blood samples and thus limited power in this population. No 
associations with HDL-C or triglycerides were evident. Ever overweight at 6-24 months 
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yielded unadjusted (eTable 3) and adjusted estimates for early adolescent FMI, HOMA-IR 
and, metabolic risk z-score and odds of obesity (Figures 1A-D) that did not differ greatly 
across WFL and BMI cut-points. In Project Viva, the adjusted estimates (in kg/m2) and F-
statistics for FMI were ‒ CDC WFL: β 0.9 (95% CI 0.5,1.4), F-statistic = 17.1; WHO WFL: 
1.1 (0.6,1.6), F-statistic = 17.3; WHO BMI: 1.4 (0.9,1.9), F-statistic = 17.8. No interactions 
were observed between ethnicity and overweight status for any outcomes in Project Viva (all 
pint > 0.05). In PROBIT, the adjusted estimates for FMI were similar in direction but of lower 
magnitude ‒ CDC WFL: 0.5 (0.4,0.6), F-statistic= 88.7; WHO WFL: 0.6 (0.5,0.7), F-statistic 
= 88.3; WHO BMI: 0.6 (0.5,0.6), F-statistic = 87.1. In comparing the F-statistics, we 
observed that none of the metrics was superior (>=5% larger) to the others. Similar findings 
were observed for other outcomes (eTable 3).  
 In both cohorts, we observed adjusted estimates of association with adolescent FMI 
(Figure 1A), BMI z-score, sum of SS and TR skinfolds, WC (eTables 4‒7), HOMA-IR 
(Figure 1B), metabolic risk z-score (Figure 1C) and odds of obesity (Figure 1D) in early 
adolescence that were generally higher with increasing age (from 6 to 24 months) at 
overweight. No associations with HDL-C or triglycerides were observed, nor did we see any 
interactions in Project Viva between ethnicity and overweight status for all outcomes (pint > 
0.05). Choice of WFL or BMI to define overweight at each time point between 6 and 24 
months did not greatly affect the unadjusted (eTables 4-7) or adjusted estimates of 
associations with FMI, HOMA-IR, metabolic risk z-score and odds of obesity (Figures 1A-
D). In comparing the F-statistics, neither growth metric was superior to the others. Similar 
findings were observed for other outcomes (eTables 4‒7).  
In PROBIT, each additional time point from 6 to 24 months at which the child was 
overweight was associated with increasing FMI (Figure 2A), BMI z-score, sum of SS and 
TR skinfolds, WC (eTable 8), HOMA-IR (Figure 2B), metabolic risk z-score (Figure 2C) 
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and odds of obesity (Figure 2D) in early adolescence. For example, the adjusted FMI 
estimate for overweight at two vs. zero time points during 6–24 months was 0.7 kg/m2 (95% 
CI 0.6,0.9) using WHO BMI, while for overweight at 3–4 time points, the adjusted estimate 
was 1.4 kg/m2 (1.1,1.7). In Project Viva, each additional time point that the child was 
overweight during 6–24 months was associated with increasing FMI (Figures 2A) in early 
adolescence, while point estimates for HOMA-IR and metabolic risk z-score (Figures 2B-C) 
were stronger in children who were overweight at two (vs. zero) time points. For both 
cohorts, estimates using CDC or WHO cut-points were similar (eTable 8). 
Discussion 
 We found that ever being overweight in the first two years was a predictor of higher 
fat-free mass and adiposity in early adolescence. Consistent with previous findings,32 the 
CDC WFL cut-point classified more children as overweight than the WHO WFL or BMI 
cutpoints. This is not surprising, given that the CDC charts used a lower percentile cut-point 
than WHO charts for classifying overweight.5,6 More importantly, the estimates of 
association with fat mass index, insulin resistance and metabolic risk score in early 
adolescence did not differ greatly among the three cut-points. 
Our findings suggest that choice of WFL or BMI in children below 2 years does not 
greatly affect the ability to predict future adiposity and cardio-metabolic outcomes. Earlier 
studies8,33 have identified high concordance between WFL and BMI after 6 months of age, 
indicating that either metric may be a reasonable measure in later infancy for assessing risk of 
later health outcomes. BMI may be preferable to WFL for other reasons, however. Within-
subject BMI measurements have greater consistency over time than within-subject WFL 
measurements,8 suggesting greater stability of BMI vs WFL. Existing guidelines already 
suggest use of BMI for growth and obesity screening after age 2.3 Applying the same metric 
for children below 2 years would therefore streamline clinical practice. Thus if BMI replaced 
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WFL for assessment of weight status in children below 2 years, it could improve monitoring 
of longitudinal growth patterns from infancy to adulthood without the need to transition 
between differing growth metrics after 2 years.  
To date, few studies have examined the meaning of BMI calculated from recumbent 
length, or the consequences of high BMI during infancy and early childhood. Because of 
these unanswered questions, BMI is not currently recommended for clinical use in children 
below 2 years.3 Recent studies, however, have indicated that BMI may be a suitable proxy of 
adiposity in older infants34-36 that also provides information about future obesity37-39 and 
cardio-metabolic risk40-42 in later childhood. We have also demonstrated that high BMI in the 
first 2 years is predictive of adiposity and metabolic risk in early adolescence, with estimates 
that are comparable to those for high WFL. We do acknowledge, however, that our findings 
would benefit from replication in other population cohorts from different settings. 
Furthermore, associations with outcomes other than adiposity or cardio-metabolic risk might 
differ. 
The strength of the associations observed was smaller for children in PROBIT than 
for those in Project Viva. We speculate that this difference is because children in PROBIT 
were larger in size during infancy than those in Project Viva (as indicated by the higher 
overweight prevalence in PROBIT infants than in Project Viva), while adolescent adiposity 
was higher in Project Viva than in PROBIT. It is likely that these growth metrics contribute a 
smaller explained variance for cardio-metabolic risk markers such as insulin resistance and 
metabolic risk score (as indicated by the small effect sizes in both cohorts) than true 
adiposity-related outcomes such as FMI. 
Our findings address important evidence gaps. First, we have shown that both CDC 
and WHO cut-points for infant or early childhood overweight provided similar adjusted 
estimates and model predictive values for cardio-metabolic outcomes in early adolescence. 
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This suggests that if pediatricians were to switch from using CDC WFL ≥95th percentile to 
WHO WFL or BMI ≥97.7th percentile in the first 2 years, the ability to predict future cardio-
metabolic outcomes would not be greatly affected. Second, we have shown that growth 
percentiles in children below 2 years that are indicative of potential health problems (i.e., 
high WFL or BMI) are associated with direct measures of adiposity and cardio-metabolic risk 
later in life. Third, we have provided evidence on the clinical implications of using WFL or 
BMI percentiles in children below 2 years as predictors of future health outcomes beyond 
childhood. Previous studies7,8 were only limited to associations with risk of obesity, and to 
follow-up in childhood, rather than adolescence.  
BMI is a widely recommended metric for obesity screening in children.43-45 Children 
who were screened and underwent intensive behavioral interventions that encompassed 
nutritional counselling (e.g., providing information about healthy eating, reading food labels, 
encouraging the use of stimulus control) and physical activity, had improvements in weight 
status for up to 12 months with minimal harm from screening.45 Evidence favoring early life 
screening and subsequent interventions in children below 6 years remains scarce, however.46 
Existing obesity prevention studies in early childhood have shown only modest benefits, and 
few have examined its impact on later cardio-metabolic health.47 Further research is needed 
to develop and test preventive interventions, especially for children who are diagnosed as 
overweight/obese during early life. 
Strengths of our study include its relatively large sample size of over thirteen 
thousand children from two prospective cohorts, multiple measures of growth in early life, 
and a wide range of cardio-metabolic outcomes in early adolescence obtained by highly-
trained research staff using standardized protocols. In addition, our study benefits from the 
variability in designs and populations in two very different populations. The robustness and 
similarity of the findings in both cohorts, despite differing confounding structures (degree of 
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income inequality, health care systems) and different obesity prevalence, suggests that bias 
due to uncontrolled (residual) confounding is an unlikely explanation for the observed 
associations.  
Our study is not without limitations, however. First, we used both research-standard 
and routinely collected anthropometric measurements from well child visits across the first 2 
years of life, which may be subject to differences in agreement.48 A recent study,33 however, 
identified high agreement between these two data sources when using WFL or BMI to 
classify overweight status in children below 2 years. Second, the value of length-based 
indices such as WFL or BMI could be affected by inaccurate length assessments due to 
measurement difficulties in infants and toddlers, especially considering that length is squared 
when calculating BMI. Third, we made no attempts to standardize the measurement of length 
in infancy across hospital or polyclinic sites in PROBIT, as differences in length gain were 
not among the study’s major hypotheses during the first year of follow-up.14 As we were 
unable to assess the reliability of infant length measurements in PROBIT, the associations of 
WFL or BMI with early adolescent outcomes could have been attenuated by measurement 
error. Fourth, our study findings may not be generalizable to other ethnic groups and 
populations, since many of our participants were white (both cohorts) or university-educated 
(in Project Viva). Fifth, some children were not followed up in both cohorts. In Project Viva, 
differences between children who were or were not followed up may limit the 
generalizability of our findings. In PROBIT, however, differences in characteristics between 
subjects followed up or not were small overall and therefore unlikely to have biased our 
findings. Sixth, the use of foot-to-foot bio-impedance methods in our study may 
underestimate adiposity compared with other methods, such as the 4-compartment model.  
Comparisons between the different methods, however, have reported the validity of bio-
impedance to accurately rank individuals15,49 and groups.50 Seventh, we investigated multiple 
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cardio-metabolic outcomes, therefore increasing the risk of false-positive results. We chose 
not to adjust for multiple comparisons. Instead, the “significance” of our findings is based on 
the consistency of the associations observed across related outcomes.51 Lastly, our study did 
not address underweight status in the first 2 years using WFL or BMI, nor its associations 
with subsequent outcomes. Rather, our study focused on later cardio-metabolic sequalae, 
which are much more strongly associated with overweight than with underweight.52 
In conclusion, we found that choice of WFL vs. BMI to define overweight in infancy 
and early childhood does not greatly affect associations with adiposity and cardio-metabolic 
outcomes in early adolescence. Although our findings would benefit from replication in other 
population cohorts, they have important implications for investigators seeking to use BMI as 
a growth metric for epidemiologic research, and for clinicians monitoring the weight status of 
children below 2 years of age.   
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Figure Legends 
Figure 1: Associations of overweight status at 6‒24 months (at each timepoint and “ever” 
overweight) with (A) fat mass index, (B) HOMA-IR, (C) metabolic risk z-score, and (D) 
odds of obesity in early adolescence. Models were adjusted for the following covariates: 
Project Viva ‒ maternal age, marital status, educational attainment, pre-pregnancy BMI, total 
gestational weight gain, smoking history, glucose tolerance status, and gestational 
hypertensive disorders, and child gestational age at delivery, race/ethnicity, sex, birth weight 
for gestational age z-scores, breastfeeding status and age at outcome measurement; PROBIT 
‒ maternal age, BMI at 6.5 years postpartum, educational attainment, marital status, 
occupation, smoking during pregnancy, gestational age at delivery, child sex, birth weight for 
gestational age z-scores and age at outcome measurement. Error bars represent 95% 
confidence intervals. 
 
Figure 2: Associations of number of timepoints overweight between 6 and 24 months with 
(A) fat mass index, (B) HOMA-IR, (C) metabolic risk z-score, and (D) odds of obesity in 
early adolescence. Models were adjusted for the following covariates: Project Viva ‒ 
maternal age, marital status, educational attainment, pre-pregnancy BMI, total gestational 
weight gain, smoking history, glucose tolerance status, and gestational hypertensive 
disorders, and child gestational age at delivery, race/ethnicity, sex, birth weight for 
gestational age z-scores, breastfeeding status and age at outcome measurement; PROBIT ‒ 
maternal age, BMI at 6.5 years postpartum, educational attainment, marital status, 
occupation, smoking during pregnancy, gestational age at delivery, child sex, birth weight for 
gestational age z-scores and age at outcome measurement. Error bars represent 95% 
confidence intervals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 23 
 
Table 1: Characteristics of study subjects in Project Viva and PROBIT 
Project Viva (n=919) All 
Ever overweight 
by WHO BMI 
Never overweight 
by WHO BMI 
p 
value 
Maternal     
Age    0.70 
 <20 years 29 (3.2) 4 (2.5) 25 (3.3)  
 20-34 years 610 (66.4) 111 (68.9) 499 (65.8)  
 ≥ 35 years 280 (30.5) 46 (28.6) 234 (30.9)  
Education level    0.02 
 Not university educated 261 (28.4) 58 (36.0) 203 (26.8)  
 University educated 658 (71.6) 103 (64.0) 555 (73.2)  
Marital status    0.18 
 Married/co-habituating 851 (92.6) 145 (90.1) 706 (93.1)  
 Not married 68 (7.4) 16 (9.9) 52 (6.9)  
Maternal smoking history    0.02 
 Never smoked 650 (70.7) 105 (65.2) 545 (71.9)  
 Smoked prior to pregnancy 184 (20.0) 32 (19.9) 152 (20.1)  
 Smoked during pregnancy 85 (9.3) 24 (14.9) 61 (8.1)  
Pre-pregnancy BMI (kg/m2) 24.8 (5.2) 25.9 (6.0) 24.6 (5.0) <0.01 
Total gestational weight gain (kg) 15.6 (5.3) 16.2 (5.7) 15.4 (5.2) 0.11 
Glucose tolerance status    0.04 
 Normoglycemia 764 (83.1) 142 (88.2) 622 (82.1)  
 Isolated hyperglycemia 80 (8.7) 8 (5.0) 72 (9.5)  
 Intermediate glucose intolerance 29 (3.2) 1 (0.6) 28 (3.7)  
 Gestational diabetes 46 (5.0) 10 (6.2) 36 (4.8)  
Hypertensive disorders of pregnancy    0.73 
 Normal blood pressure 822 (89.4) 142 (88.2) 680 (89.7)  
 Gestational hypertension 63 (6.9) 11 (6.8) 52 (6.9)  
 Chronic Hypertension 10 (1.1) 3 (1.9) 7 (0.9)  
 Pre-eclampsia 24 (2.6) 5 (3.1) 19 (2.5)  
Child     
Sex    0.10 
 Male 460 (50.1) 90 (55.9) 370 (48.8)  
 Female 459 (49.9) 71 (44.1) 388 (51.2)  
Race/ethnicity    0.04 
 White 598 (65.1) 98 (60.9) 500 (66.0)  
 Black 143 (15.6) 38 (23.6) 105 (13.9)  
 Hispanic 39 (4.2) 6 (3.7) 33 (4.4)  
 Asian 27 (2.9) 3 (1.9) 24 (3.2)  
 Others 112 (12.2) 16 (9.9) 96 (12.7)  
Gestational age at delivery (weeks) 39.6 (1.6) 39.5 (1.7) 39.6 (1.6) 0.42 
Birthweight-for-gestational age z-score (SD units) 0.2 (1.0) 0.4 (0.9) 0.2 (1.0) <0.01 
Breastfeeding status at 6 months    <0.01 
 Formula only 79 (9.1) 13 (8.7) 66 (9.2)  
 Weaned 312 (35.9) 70 (47.0) 242 (33.6)  
 Mixed feeding 239 (27.5) 41 (27.5) 198 (27.5)  
 Breastmilk only 239 (27.5) 25 (16.8) 214 (29.7)  
PROBIT (n=12,747) All 
Ever overweight  
by WHO BMI 
Never overweight 
by WHO BMI 
p 
value 
Maternal     
Age    0.20 
 <20 years 1704 (13.6) 447 (14.6) 1257 (13.3)  
 20-34 years 10284 (82.1) 2491 (81.1) 7793 (82.4)  
 ≥ 35 years 542 (4.3) 134 (4.4) 408 (4.3)  
Education level    0.90 
 Did not complete university 11047 (86.7) 2718 (87.0) 8329 (86.6)  
 Completed university 1700 (13.3) 407 (13.0) 1293 (13.4)  
Marital status    0.19 
 Registered/unregistered marriage 12280 (96.3) 3027 (96.9) 9253 (96.2)  
 Unmarried 467 (3.7) 98 (3.1) 369 (3.8)  
Smoking during pregnancy    0.57 
 No 12499 (98.1) 3068 (98.2) 9431 (98.0) 
 
Yes 248 (1.9) 57 (1.8) 191 (2.0)  
BMI at 6.5 years (kg/m2) 24.5 (4.4) 24.9 (4.3) 24.3 (4.4) <0.01 
Child     
Sex    <0.01 
 Male 6204 (48.7) 1191 (38.1) 5013 (52.1)  
 Female 6543 (51.3) 1934 (61.9) 4609 (47.9)  
 24 
 
Gestational age at delivery (weeks) 39.4 (1.0) 39.4 (1.0) 39.4 (1.0) 0.40 
Birthweight-for-gestational age z-score (SD units) 0.4 (1.0) 0.6 (1.0) 0.4 (1.0) <0.01 
 25 
 
Table 2: Prevalence of overweight at 6─24 months and distributions of early adolescent 
cardio-metabolic outcomes in Project Viva and PROBIT 
 
 Project Viva 
n=919a 
PROBIT 
n=12,747a 
Overweight prevalence at 6‒24 
months 
 
Month 6 (range 4-8 months)b   
 CDC WFL
c ≥ 95th percentile 134/891 (15.0) 1521/12594 (12.1) 
 WHO WFL
d ≥ 97.7th percentile 86/891 (9.7) 998/12594 (7.9) 
 WHO BMI
e ≥ 97.7th percentile 75/891 (8.4) 895/12594 (7.1) 
Month 12 (range 10-14 months)b   
 CDC WFL ≥ 95
th percentile 64/701 (9.1) 2594/12707 (20.4) 
 WHO WFL ≥ 97.7
th percentile 50/701 (7.1) 2180/12707 (17.2) 
 WHO BMI ≥ 97.7
th percentile 54/701 (7.7) 2171/12707 (17.1) 
Month 18 (range 16-20 months)b   
 CDC WFL ≥ 95
th percentile 68/634 (10.7) 424/2965 (14.3) 
 WHO WFL ≥ 97.7
th percentile 63/634 (9.9) 396/2965 (13.4) 
 WHO BMI ≥ 97.7
th percentile 67/634 (10.6) 454/2965 (15.3) 
Month 24 (range 22-26 months)b   
 CDC WFL ≥ 95
th percentile 53/563 (9.4) 628/4590 (13.7) 
 WHO WFL ≥ 97.7
th percentile 48/563 (8.5) 567/4590 (12.3) 
 WHO BMI ≥ 97.7
th percentile 44/563 (7.8) 628/4590 (13.7) 
Ever overweightb   
 CDC WFL ≥ 95
th percentile 206/919 (22.4) 3715/12747 (29.1) 
 WHO WFL ≥ 97.7
th percentile 160/919 (17.4) 3069/12747 (24.1) 
 WHO BMI ≥ 97.7
th percentile 161/919 (17.5) 3125/12747 (24.5) 
Early adolescent outcomes   
 Height z-score (SD units)f 0.3 (1.0) 0.3 (1.0) 
 BMI z-score (SD units)f 0.4 (1.1) -0.1 (1.0) 
 Sum of skinfolds (mm)f 28.4 (13.9) 23.1 (11.4) 
 Fat mass index (kg/m2)f 4.9 (3.5) 3.3 (2.2) 
 Waist circumference (cm)f 73.0 (11.8) 64.8 (8.1) 
 Systolic BP z-score (SD units)f -0.1 (0.8) 0.4 (0.8) 
 HOMA-IRg 2.6 (2.1) 0.9 (1.2) 
 HDL-cholesterol (mg/dL)f 55.2 (13.6) NAh 
 Triglycerides (mg/dL)f 70.3 (31.1) NAh 
 Apolipoprotein A1 (g/L) NAh 1.6 (0.4) 
 Metabolic risk score (SD units)f -0.02 (0.6) 0.01 (0.5) 
 Obesityb 113 (12.3) 632 (5.0) 
a Sample size is based on those who had a measure of weight and length at 6, 12, 18 or 24 months (within ±2 
months at each timepoint) and at least one outcome measure at the early adolescent visit 
b Numbers represent N (%) 
c CDC WFL: Center for Disease Control and Prevention weight-for-length 
d WHO WFL: World Health Organization weight-for-length 
e WHO BMI: World Health Organization body mass index 
f Numbers represent mean (SD) 
g Numbers represent median (interquartile range) 
h NA: Not applicable 
